BrightPath Biotherapeutics Co., Ltd.
JPX: 4594.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kenichi Nagai
- Employees
- 42
- Headquarters
- Tokyo, Japan
- IPO year
- 2015
- Market cap
- ¥5.2B
- Website
- https://www.brightpathbio.com
Loading 4594…
Loading profile data…Frequently asked questions about 4594
What does BrightPath Biotherapeutics Co., Ltd. (4594.T) do?
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cance...
Where does 4594.T trade?
BrightPath Biotherapeutics Co., Ltd. (4594.T) trades on the Tokyo Stock Exchange.
What sector is 4594.T in?
BrightPath Biotherapeutics Co., Ltd. (4594.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BrightPath Biotherapeutics Co., Ltd.?
Kenichi Nagai is the chief executive officer of BrightPath Biotherapeutics Co., Ltd. (4594.T).
Where is BrightPath Biotherapeutics Co., Ltd. headquartered?
BrightPath Biotherapeutics Co., Ltd. is headquartered in Japan.
Does 4594.T pay a dividend?
BrightPath Biotherapeutics Co., Ltd. (4594.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4594.T go public?
BrightPath Biotherapeutics Co., Ltd. (4594.T) completed its initial public offering in 2015.